Cholangiocarcinoma.

Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg (2007) 3.73

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.90

Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol (2009) 2.17

Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One (2011) 1.98

Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents. Dig Dis Sci (2011) 1.71

Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2006) 1.68

MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin. Gastroenterology (2012) 1.48

Endoscopic and percutaneous preoperative biliary drainage in patients with suspected hilar cholangiocarcinoma. J Gastrointest Surg (2009) 1.45

Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study. Gut Liver (2009) 1.43

Cholangiographic spectrum of intraductal papillary mucinous neoplasm of the bile ducts. Ann Surg (2006) 1.36

Current surgical treatment for bile duct cancer. World J Gastroenterol (2007) 1.30

A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. Gastroenterology (2011) 1.29

Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol (2008) 1.23

Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc (2014) 1.21

Cancer review: Cholangiocarcinoma. J Carcinog (2015) 1.17

Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Carcinogenesis (2011) 1.13

Endoscopic transpapillary brush cytology and forceps biopsy in patients with hilar cholangiocarcinoma. World J Gastroenterol (2008) 1.09

Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci (2011) 1.08

Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol (2008) 1.07

Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol (2008) 1.05

Molecular pathogenesis of cholangiocarcinoma. Int J Hepatol (2011) 1.02

Endoscopic stenting for hilar cholangiocarcinoma: efficacy of unilateral and bilateral placement of plastic and metal stents in a retrospective review of 480 patients. BMC Gastroenterol (2012) 1.01

miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One (2013) 1.00

Leptin enhances cholangiocarcinoma cell growth. Cancer Res (2008) 1.00

Photodynamic therapy for unresectable cholangiocarcinoma. Dig Dis Sci (2011) 1.00

Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells. J Gastroenterol (2011) 0.96

Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer (2010) 0.96

Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets. Liver Int (2007) 0.95

Confocal endomicroscopic examination of malignant biliary strictures and histologic correlation with lymphatics. J Clin Gastroenterol (2011) 0.94

New insights on cholangiocarcinoma. World J Gastrointest Oncol (2010) 0.94

CEACAM6 gene expression in intrahepatic cholangiocarcinoma. Br J Cancer (2006) 0.94

A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma. Ann Surg Oncol (2013) 0.93

Diagnosis of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg (2008) 0.92

The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. Hum Pathol (2013) 0.92

Surgical strategy for bile duct cancer: Advances and current limitations. World J Clin Oncol (2011) 0.92

Nervous and Neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis. World J Gastroenterol (2006) 0.91

Survival analysis of cholangiocarcinoma: a 10-year experience in Malaysia. World J Gastroenterol (2012) 0.91

Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-enhanced MRI. Eur Radiol (2015) 0.89

Impact of Salinomycin on human cholangiocarcinoma: induction of apoptosis and impairment of tumor cell proliferation in vitro. BMC Cancer (2012) 0.89

Staging of extrahepatic cholangiocarcinoma. Eur Radiol (2008) 0.89

Diagnosis of pancreaticobiliary malignancy by detection of minichromosome maintenance protein 5 in bile aspirates. Br J Cancer (2008) 0.89

Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways. J Hepatol (2006) 0.88

Surgery for extrahepatic cholangiocarcinoma: predictors of survival. HPB (Oxford) (2008) 0.88

R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer. Liver Int (2010) 0.88

Primary sclerosing cholangitis--what is the difference between east and west? World J Gastroenterol (2008) 0.88

Differentiation of malignant and benign proximal bile duct strictures: the diagnostic dilemma. World J Gastroenterol (2008) 0.88

Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma. EBioMedicine (2016) 0.87

Adjuvant radio-chemotherapy for extrahepatic biliary tract cancers. BMC Cancer (2011) 0.87

Current status of intrahepatic cholangiocarcinoma. World J Gastroenterol (2008) 0.87

Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach. World J Gastroenterol (2007) 0.87

Endomicroscopy in bile duct: Inflammation interferes with pCLE applied in the bile duct: A prospective study of 54 patients. United European Gastroenterol J (2013) 0.85

Genome-wide screen identified let-7c/miR-99a/miR-125b regulating tumor progression and stem-like properties in cholangiocarcinoma. Oncogene (2015) 0.85

Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells. Int J Biol Sci (2011) 0.85

Photodynamic therapy: Palliation and endoscopic technique in cholangiocarcinoma. World J Gastrointest Endosc (2010) 0.85

Control of cholangiocyte adaptive responses by visceral hormones and neuropeptides. Clin Rev Allergy Immunol (2009) 0.85

Identification of novel biomarker candidates for the immunohistochemical diagnosis of cholangiocellular carcinoma. Mol Cell Proteomics (2014) 0.85

Endoscopic stent placement in the palliation of malignant biliary obstruction. Clin Endosc (2011) 0.85

MicroRNAs associated with the efficacy of photodynamic therapy in biliary tract cancer cell lines. Int J Mol Sci (2014) 0.84

A chimeric antibody to L1 cell adhesion molecule shows therapeutic effect in an intrahepatic cholangiocarcinoma model. Exp Mol Med (2012) 0.84

Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression. Gastroenterology (2011) 0.84

5-aminolevulinic acid-incorporated poly(vinyl alcohol) nanofiber-coated metal stent for application in photodynamic therapy. Int J Nanomedicine (2012) 0.83

Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review. HPB (Oxford) (2013) 0.83

Changing perspectives in the assessment of resectability of hilar cholangiocarcinoma. Ann Surg Oncol (2007) 0.83

Photodynamic therapy for cholangiocarcinoma. Gut Liver (2010) 0.82

Molecular mechanisms of cholangiocarcinoma. World J Gastrointest Pathophysiol (2010) 0.82

Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth. Dig Liver Dis (2008) 0.82

The associated expression of Maspin and Bax proteins as a potential prognostic factor in intrahepatic cholangiocarcinoma. BMC Cancer (2006) 0.82

Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues. Oncologist (2012) 0.82

Human gallbladder carcinoma: Role of neurotrophins, MIB-1, CD34 and CA15-3. Eur J Histochem (2010) 0.81

Hilar cholangiocarcinoma: Cross sectional evaluation of disease spectrum. Indian J Radiol Imaging (2015) 0.81

Prognostic factors in patients with advanced cholangiocarcinoma: role of surgery, chemotherapy and body mass index. World J Gastroenterol (2008) 0.81

β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma. World J Gastroenterol (2015) 0.81

Liver transplantation for cholangiocarcinoma: Current status and new insights. World J Hepatol (2015) 0.81

A review on the use of confocal laser endomicroscopy in the bile duct. Gastroenterol Res Pract (2012) 0.80

Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors. Cancer Prev Res (Phila) (2013) 0.80

Triple modality testing by endoscopic retrograde cholangiopancreatography for the diagnosis of cholangiocarcinoma. Therap Adv Gastroenterol (2015) 0.80

Targeted therapy for biliary tract cancer. Cancers (Basel) (2011) 0.80

Cholangiocarcinoma: a 7-year experience at a single center in Greece. World J Gastroenterol (2008) 0.79

Aberrant DNA methylation profile in cholangiocarcinoma. World J Gastrointest Pathophysiol (2010) 0.79

Prognostic Significance of Neutrophil to Lymphocyte Ratio in Oncologic Outcomes of Cholangiocarcinoma: A Meta-analysis. Sci Rep (2016) 0.79

Cholangiocarcinoma developed in a patient with IgG4-related disease. World J Gastrointest Oncol (2013) 0.79

Different carcinogenic process in cholangiocarcinoma cases epidemically developing among workers of a printing company in Japan. Int J Clin Exp Pathol (2014) 0.79

HOXD10 acts as a tumor-suppressive factor via inhibition of the RHOC/AKT/MAPK pathway in human cholangiocellular carcinoma. Oncol Rep (2015) 0.79

Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth. Am J Physiol Gastrointest Liver Physiol (2014) 0.78

The significance of genetics for cholangiocarcinoma development. Ann Transl Med (2013) 0.78

The effects of buthionine sulfoximine on the proliferation and apoptosis of biliary tract cancer cells induced by cisplatin and gemcitabine. Oncol Lett (2015) 0.78

EC-18, a synthetic monoacetyldiacylglyceride, inhibits hematogenous metastasis of KIGB-5 biliary cancer cell in hamster model. J Korean Med Sci (2009) 0.78

Utilizing signature-score to identify oncogenic pathways of cholangiocarcinoma. Transl Cancer Res (2013) 0.77

Early bile duct cancer. World J Gastroenterol (2007) 0.77

Retinoid X receptor α enhances human cholangiocarcinoma growth through simultaneous activation of Wnt/β-catenin and nuclear factor-κB pathways. Cancer Sci (2015) 0.77

Genetic and molecular abnormalities in cholangiocarcinogenesis. Anticancer Res (2009) 0.77

Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: a meta-analysis. World J Gastroenterol (2014) 0.77

Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents. J Exp Clin Cancer Res (2014) 0.77

Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression. Cancer Res (2015) 0.77

Apoptosis of human cholangiocarcinoma cells induced by ESC-3 from Crocodylus siamensis bile. World J Gastroenterol (2012) 0.76

Pancreatic recurrence of intrahepatic cholangiocarcinoma: Case report and review of the literature. World J Gastrointest Surg (2014) 0.75

Diagnosis of pancreaticobiliary malignancy by detection of minichromosome maintenance protein 5 in biliary brush cytology. Br J Cancer (2017) 0.75

Sodium iodide symporter and phosphatase and tensin homolog deleted on chromosome ten expression in cholangiocarcinoma analysis with clinicopathological parameters. Gut Liver (2012) 0.75

Defensive mechanism in cholangiocarcinoma cells against oxidative stress induced by chlorin e6-based photodynamic therapy. Drug Des Devel Ther (2014) 0.75

Diagnosis and surgical treatment of intrahepatic hepatolithiasis combined with cholangiocarcinoma. World J Surg (2014) 0.75

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79

Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84

Mechanisms of hepatotoxicity. Toxicol Sci (2002) 4.13

Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95

Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60

Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem (2006) 3.57

Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology (2006) 3.52

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36

Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23

Cellular and molecular mechanisms of liver injury. Gastroenterology (2008) 3.02

Lysosomes in cell death. Oncogene (2004) 3.00

Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89

Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81

Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70

Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl (2015) 2.63

EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc (2007) 2.61

Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest (2012) 2.56

Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51

Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology (2003) 2.45

Life and death by death receptors. FASEB J (2009) 2.39

Cholangiocarcinoma. Clin Liver Dis (2008) 2.33

Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology (2012) 2.33

Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest (2014) 2.31

Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol (2003) 2.29

Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23

A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol (2004) 2.23

MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23

Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19

Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18

Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis (2005) 2.18

Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03

Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03

Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem (2007) 2.01

Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01

Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut (2007) 1.99

Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology (2002) 1.98

Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest (2010) 1.97

Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest (2003) 1.96

Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology (2006) 1.93

Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res (2004) 1.91

The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology (2008) 1.88

Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology (2003) 1.86

A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol (2004) 1.83

JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem (2009) 1.82

Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol (2004) 1.80

Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology (2005) 1.78

Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest (2003) 1.73

Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70

Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2006) 1.68

A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol (2004) 1.66

Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol (2006) 1.66

A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology (2008) 1.65

Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl (2007) 1.64

Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem (2007) 1.63

Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci (2005) 1.63

The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63

Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology (2006) 1.60

The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther (2003) 1.60

Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58

Liver transplantation for cholangiocarcinoma. Transpl Int (2010) 1.58

Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol (2010) 1.56

Apoptosis and cellular activation in the pathogenesis of acute vascular rejection. Circ Res (2002) 1.56

Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology (2009) 1.55

Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol (2012) 1.55

CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am J Physiol Gastrointest Liver Physiol (2010) 1.54

Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford) (2011) 1.54

Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol (2005) 1.53

Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology (2010) 1.53

IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology (2015) 1.52

"Will all liver transplantation patients eventually die from cancer?". J Hepatol (2005) 1.52

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol (2012) 1.51

Caveolin-1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway. Arterioscler Thromb Vasc Biol (2003) 1.50

Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology (2009) 1.49

Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol (2003) 1.48

Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am J Physiol Gastrointest Liver Physiol (2002) 1.47

The emergence of a new discipline, hepatobiliary oncology. Hepatology (2008) 1.46

TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology (2008) 1.45

Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. J Biol Chem (2007) 1.43

Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.43

Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation (2006) 1.43

Comparison of methods to detect neoplasia in patients undergoing endoscopic ultrasound-guided fine-needle aspiration. Gastroenterology (2012) 1.43

Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol (2013) 1.43

Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology (2006) 1.42

Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species. Hepatology (2008) 1.41

Primary sclerosing cholangitis: summary of a workshop. Hepatology (2006) 1.38

Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res (2002) 1.37

Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology (2005) 1.37

Death receptor-mediated apoptosis and the liver. J Hepatol (2002) 1.37

Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem (2002) 1.36

Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr (2011) 1.35

Mechanisms of liver injury: an overview. Curr Mol Med (2003) 1.34

Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis (2004) 1.34

Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol (2005) 1.32

Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J Biol Chem (2003) 1.32

Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology (2002) 1.31

Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology (2005) 1.27

The anti-apoptotic protein Mcl-1 inhibits mitochondrial Ca2+ signals. J Biol Chem (2005) 1.24

Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis. PLoS One (2013) 1.23